Breast cancer
Unicancer funds a broad programme in breast cancer, with strong activity in hormone receptor-positive, HER2-negative, and triple-negative breast cancer settings. Its trials address early breast cancer, metastatic breast cancer, brain metastases, leptomeningeal disease, and treatment adaptation based on ctDNA and molecular markers.
- ER-positive / HER2-negative disease
- Triple-negative breast cancer
- HER2-positive and HER2-low breast cancer
- Molecular profiling and circulating tumour DNA
Research also includes endocrine therapy, CDK4/6 inhibition, antibody-drug conjugates, and risk-adapted strategies for patients with residual disease or low-risk recurrence profiles.
Genitourinary cancers
The sponsor supports trials in prostate cancer, bladder cancer, and penile cancer, spanning localized, recurrent, and metastatic disease. Key interests include castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and high-risk relapse settings after local treatment.
- Prostate adenocarcinoma
- Muscle-invasive bladder cancer
- Non-muscle invasive bladder cancer
- Squamous cell carcinoma of the penis
Clinical research in this area includes androgen receptor-targeted therapy, radiotherapy, functional imaging-guided treatment, and PSMA-based approaches.
Gastrointestinal and hepatobiliary cancers
Unicancer is active in colorectal cancer, gastric cancer, esophagogastric junction adenocarcinoma, oesophageal cancer, biliary tract cancer, and hepatocellular carcinoma. The portfolio includes both localized and advanced disease, with attention to biomarker-defined populations and treatment resistance.
- Colorectal cancer
- Gastric and gastroesophageal junction adenocarcinoma
- Biliary tract cancer
- Hepatocellular carcinoma
Research topics include immune checkpoint inhibition, targeted therapy, chemoradiotherapy, and treatment selection in the presence of DPD deficiency or other actionable biomarkers.
Thoracic and head and neck malignancies
Its oncology programme also covers non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma of the head and neck, and related squamous malignancies. Trials address both first-line and maintenance treatment strategies in advanced and locally advanced settings.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Esophageal squamous cell carcinoma
Areas of interest include immunotherapy, radiotherapy, and treatment of frail or older patients with advanced thoracic disease.
Sarcoma, melanoma, and biomarker-driven solid tumours
Unicancer supports research in soft tissue sarcoma, osteosarcoma, uterine leiomyosarcoma, and melanoma, alongside basket studies in biomarker-selected solid tumours. These trials include patients with BRAF alterations, FGFR alterations, HER2 changes, and MSI-H or dMMR profiles.
- Soft tissue and bone sarcomas
- Melanoma with brain metastasis
- FGFR-altered solid tumours
- BRAF-mutated malignancies
Research in this category includes intratumoral immunotherapy, molecularly guided treatment, and approaches for advanced cancers with limited standard options.
